查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1837278

伤口生技药品市场（按产品类型、应用、最终用户和分销管道）—全球预测 2025-2032

Wound Biologics Market by Product Type, Application, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年伤口生技药品市场将成长至 120.1 亿美元，复合年增长率为 10.42%。

主要市场统计数据
基准年2024年 54.3亿美元
预计2025年 59.9亿美元
预测年份：2032年 120.1亿美元
复合年增长率（%） 10.42%

一份全面的方向摘要，描述了当前影响伤口生物製药领域的技术驱动因素、临床重点和策略动机

由于科学进步、护理途径的转变以及医疗保健相关人员日益增长的商业性兴趣，伤口生物製药的模式正在迅速演变。本简介概述了伤口生物製药的现代格局，重点介绍了主要的治疗方法类别，并解释了为什么对伤口生物製药的战略关注对于临床医生、医院系统和生命科学投资者至关重要。

生医材料、再生医学和即时医疗服务领域的最新进展，正在将伤口护理从单纯的症状治疗转变为有针对性的生物干预。因此，临床医生正在寻求能够整合支架性能、生长因子活性和自体製剂，并具有明确操作和安全特性的产品。同时，医疗系统和门诊医疗服务提供者正在重新调整采购和护理路径，以优先考虑能够减少併发症、加快癒合时间并优化资源利用率的治疗方法。本引言概述了将在不久的将来影响商业性和临床决策的关键技术发展轨迹、报销考量和相关人员期望，为后续章节奠定了基础。

技术创新、监管透明度和医疗保健服务改革如何重塑伤口生物製药的竞争态势和采用途径

伤口生物製药领域正在经历一场变革性的转变，融合了科学创新、监管变革和医疗服务改革。在产品层面，支架工程、精准生长因子製剂、自体血小板衍生物等领域的改进，正在提升治疗的特异性与效用。这些技术进步与监管途径相辅相成，监管途径日益认可生物製药与传统外用药物截然不同的风险-效益特征，从而在安全和生产控製到位的前提下，为生物製剂的临床应用提供了更清晰的路径。

同时，交付模式也在改变。医院和创伤护理中心正在更早地将生物製药纳入其护理演算法，而门诊手术中心和居家照护提供者则正在采用专为简单环境设计的精简产品。支付模式和基于价值的合约正在鼓励製造商展示其在现实世界中的有效性和可预测的结果。总而言之，这些转变创造了一个更具竞争力的环境，其中临床差异化、供应链弹性和证据产生至关重要。研发、监管和商业职能之间的策略协调将决定哪些组织能够从这些结构性变化中获益。

评估近期关税措施对伤口生技药品采购决策、供应链弹性和采购行为的系统性影响

2025年高关税的实施对伤口生物製药的采购、生产策略和采购惯例产生了重大的下游影响。对进口原料、成品和生物製药成分征收的关税增加了到岸成本，促使製造商重新评估其成分采购，并重新关注近岸外包和供应基础多元化。这迫使契约製造製造商和供应商重新评估其成本模型和库存策略，以确保向临床客户提供持续供应的同时保护净利率。

贸易政策的这些转变也间接影响临床应用模式。医院和伤口护理中心的采购团队在评估供应商合作关係时，越来越重视整体拥有成本和供应的确定性。此外，一些创新企业正在加快本地製造投资和技术转让，以减轻关税的影响并缩短前置作业时间。总体而言，2025年的关税环境正在将供应链策略推向商业性需求的核心，使得弹性、灵活性和成本透明度对于永续的市场准入至关重要。

将产品模式、临床适应症、医疗保健环境和分销管道与策略商业化机会联繫起来的详细細項分析

详细的细分揭示了每种产品、最终用途、最终用户和分销管道类别的明确价值驱动因素、临床用例和商业性途径。产品类型包括胶原蛋白、生长因子、血小板衍生物和皮肤替代。胶原蛋白配方来自牛、马和猪，具有不同的免疫抗原性和处理特性，会影响临床医师的偏好和监管策略。生长因子包括表皮生长因子、纤维母细胞生长因子、血小板衍生生长因子和血管内皮生长因子，每种都有独特的作用机制，指南适应症定位和组合方法。以富血小板纤维蛋白和富血小板血浆为代表的血小板衍生物的独特之处在于它们是自体的即时护理干预措施，可改变程序工作流程。皮肤替代品包括生物真皮、复合真皮和合成真皮结构，每种结构都在生物完整性和製造一致性之间进行权衡。

急性伤口、烧伤、慢性伤口和外科性创伤各自需要不同的临床终点和证据。烧伤细分为二度和三度，而慢性伤口包括糖尿病足溃疡、压疮和下肢静脉溃疡，每种伤口都需要量身定制的治疗策略。最终用户种类繁多，包括门诊手术中心、居家医疗中心、医院和伤口护理中心。最后，分销管道大致分为线下和线上，线下包括传统的临床经销商和医院供应链，线上则透过直接销售给医疗机构和机构电商平台而发展。这些细分领域的整合表明，临床需求、营运可行性和商业规模的一致性有利于特定的技术和市场方法。

区域比较揭示了管理体制、付款人优先事项和医疗保健基础设施如何决定全球市场的采取路径

美洲、欧洲、中东和非洲以及亚太市场的区域动态正在以不同的方式影响技术采用、报销政策和供应链策略。美洲凭藉其强大的临床基础设施和成熟的伤口护理专科网络，往往率先采用那些展现出临床差异化和运营效率的新型生物製药。这些市场也优先考虑循证试验和整合护理路径，从而推动了对展现出以患者为中心的疗效的产品的需求。

在欧洲、中东和非洲，不同的监管和付款人制度要求制定区域性打入市场策略。有些地区强调成本效益和集中采购，而其他地区则依赖专业中心来推动创新。亚太地区的临床能力和製造投资正在快速扩张，这不仅推动了需求，也激发了区域生产规模的潜力。由于全部区域在临床医生培训、报销制度和供应链基础设施方面存在差异，製造商需要采用针对特定地区的循证计划、经销伙伴关係和监管策略，以实现大规模应用。

评估创新通路、生产规模和证据产生能力的竞争定位，以及推动差异化的策略性倡议

伤口生技药品的竞争态势由差异化的科学平台、製造能力和实证组合决定。领先的技术开发商正在投资下一代支架化学、多因子生长因子组合和标准化自体处理系统，而契约製造和组件供应商则正在扩展其能力，以满足生技药品严格的品质和无菌要求。策略活动还包括与临床领导者和产品开发人员合作，共同设计符合实际伙伴关係的处理和应用通讯协定。

此外，推动支付方和医院购买的差异化，例如上市后资料收集、真实世界证据生成和健康经济模型，正变得越来越重要。一些公司优先采用垂直整合的方法来控制供应链风险，而其他公司则正在建立合作伙伴关係，以将分销扩展到门诊和居家医疗管道。随着市场的成熟，我们预计围绕整合平台的整合将会增加，这些平台将结合强大的临床结果、扩充性的生产和可靠的分销，从而为新参与企业设置更高的门槛。

製造商和医疗保健提供者应采取的具体、优先行动，以协调创新重点、加强供应链并加速伤口生物製药的临床和付款人采用

产业领导者应采取一系列协作行动，在管理商业性和营运风险的同时，充分利用科学进步。首先，应根据医院、创伤护理中心、门诊手术中心和居家照护机构的处理、储存和使用习惯，开发客製化产品，使研发重点与医疗点的需求保持一致。其次，应透过采购多元化、近岸外包和策略性库存政策，提升供应链韧性，以降低贸易政策变化和物流中断带来的风险。

第三，投资于严谨的临床和健康经济证据，以解决付款方的担忧并推动相关途径的采用。务实的临床试验和真实世界註册可以加速报销讨论。第四，协调区域市场准入计划，以反映当地的法规结构和采购动态，确保市场准入顺序针对报销和临床医生参与度进行优化。最后，探索将产品与培训、数位追踪和结果衡量相结合的伙伴关係模式，以提供差异化的价值提案，吸引临床和经济相关人员的参与。

透明的混合方法研究框架，结合临床医生访谈、技术文献综述和供应链分析，以检验临床和商业性相关的发现

这项综合性研究采用混合方法，整合了初步定性访谈、二手文献综述、产品技术文件和供应链图谱，旨在对伤口生技药品领域形成严谨且可操作的视角。主要资讯包括对医院内临床医生、伤口护理专家、采购主管、监管专家和生产合作伙伴进行结构化访谈，以了解实际使用模式、未满足的临床需求和采购考量。这些观点与监管指南、同行评审的科学文献和产品标籤资讯相互参照，以检验其作用机制和安全性。

此外，供应链分析利用贸易流量数据、零件采购审查和製造外包评估来揭示关税和製造风险的影响。透过将产品属性映射到临床适应症和最终用户工作流程，建立了细分框架；分销管道分析则评估了交易摩擦点和数位化应用趋势。研究结果透过相关人员的回馈进行迭代检验，以确保其对商业性和临床决策者的相关性和实际适用性。

对伤口生技药品进行全面、前瞻性的检视，强调需要製定涵盖研发、供应链和市场进入的整合策略，以确保其持续优势。

总而言之，伤口生物製药领域正处于曲折点，科学进步、护理模式的转变以及商业性压力既带来了机会，也带来了复杂性。将强大的生物功能与实用的临床操作和可靠的供应相结合的技术很可能会在早期获得应用。同时，不断变化的贸易政策和报销预期意味着製造商必须对其产品的生产地点和方式、价格以及支持的证据进行策略性考虑。

展望未来，拥有从研发和法规事务到供应链和市场进入的一体化跨职能规划的组织将最有可能获得持久价值。成功取决于展示现实世界的成果、维持生产和分销的韧性，以及根据不同付款方和临床情况，根据地区实施差异化的商业化策略。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 在门诊创伤护理环境中快速采用照护现场自体富血小板血浆系统
  • 扩大异体干细胞治疗慢性糖尿病足和静脉性腿部溃疡
  • 3D生物列印技术整合客製化细胞外基质支架用于伤口修復
  • 更重视先进生物伤口护理的成本效益与报销途径
  • 加速监管人类胎盘羊膜产品，取得突破性医疗设备认定
  • 人们对将生长因子与生物活性奈米纤维基质相结合以加速癒合的联合治疗的兴趣日益浓厚。
  • 远距远端医疗伤口监测平台与生物治疗管理工具结合的出现
  • 开发病原体减少的去细胞异种移植膜以最大限度地减少慢性伤口的免疫抗原性原性反应

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 伤口生技药品市场（依产品类型）

  • 胶原蛋白
    • 牛胶原蛋白
    • 马胶原蛋白
    • 猪肉胶原蛋白
  • 生长因子
    • 表皮生长因子
    • 纤维母细胞生长因子
    • 血小板衍生生长因子
    • 血管内皮生长因子
  • 血小板衍生物
    • 富含血小板的纤维蛋白
    • 富血小板血浆
  • 皮肤替代品
    • 生物皮肤
    • 复合蒙皮
    • 合成皮肤

9. 伤口生技药品市场（依应用）

  • 急性伤口
  • 烧烫伤
    • 二度烧伤
    • 三度烧伤
  • 慢性伤口
    • 糖尿病足溃疡
    • 压疮
    • 静脉性腿部溃疡
  • 手术伤口

第 10 章伤口生技药品市场（以最终用户划分）

  • 门诊手术中心
  • 居家护理
  • 医院
  • 创伤护理中心

第 11 章伤口生技药品市场（依通路）

  • 离线
  • 在线的

12. 伤口生技药品市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 13 章伤口生技药品市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 14 章伤口生技药品市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • 3M Company
    • Organogenesis Inc.
    • Smith & Nephew plc
    • Molnlycke Health Care AB
    • Integra LifeSciences Holdings Corporation
    • MiMedx Group, Inc.
    • Celularity, Inc.
    • Avita Medical Ltd.
    • Alliqua BioMedical, Inc.
    • CollPlant Biotechnologies Ltd.
Product Code: MRR-0315DDADCE4B

The Wound Biologics Market is projected to grow by USD 12.01 billion at a CAGR of 10.42% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.43 billion
Estimated Year [2025] USD 5.99 billion
Forecast Year [2032] USD 12.01 billion
CAGR (%) 10.42%

A comprehensive orienting summary that explains current technological drivers, clinical priorities, and strategic motivations shaping the wound biologics sector

The wound biologics landscape is rapidly evolving, driven by scientific progress, changing care pathways, and heightened commercial interest across healthcare stakeholders. This introduction distills the field's contemporary contours, clarifies the principal classes of therapeutic modalities, and frames why strategic attention to biologic wound therapies is now imperative for clinicians, hospital systems, and life sciences investors.

Recent advances in biomaterials, regenerative medicine, and point-of-care delivery have shifted wound care from purely symptomatic management to targeted biological intervention. As a result, clinicians seek products that integrate scaffold performance, growth factor activity, and autologous preparations with clear handling and safety profiles. Meanwhile, health systems and ambulatory providers are recalibrating procurement and care pathways to prioritize therapies that reduce complications, shorten healing times, and optimize resource utilization. This introduction sets the context for the subsequent sections by outlining key technological trajectories, reimbursement considerations, and cross-stakeholder expectations that together shape near-term commercial and clinical decision-making.

How converging technical innovations, regulatory clarity, and care delivery reforms are reshaping competitive dynamics and adoption pathways across wound biologics

The wound biologics sector is experiencing transformative shifts that recombine scientific innovation, regulatory evolution, and care delivery reforms. At the product level, improvements in scaffold engineering, precision growth factor formulations, and autologous platelet derivatives are enhancing therapeutic specificity and usability. These technological advances are complemented by regulatory pathways that increasingly recognize the distinct risk-benefit profiles of biologics versus traditional topical agents, allowing clearer pathways to clinical adoption when safety and manufacturing controls are robust.

Concurrently, delivery models are changing: hospitals and wound care centers are integrating biologic therapies earlier in care algorithms, while ambulatory surgical centers and home care providers are adopting streamlined products designed for lower-complexity settings. Payment models and value-based contracting are nudging manufacturers to demonstrate real-world effectiveness and predictable outcomes. Taken together, these shifts create a more competitive environment in which clinical differentiation, supply chain resilience, and evidence generation are decisive. Strategic alignment across R&D, regulatory affairs, and commercial functions will determine which organizations capitalize on these structural changes.

Evaluating the systemic consequences of recent tariff actions on sourcing decisions, supply chain resilience, and procurement behaviors within wound biologics

The introduction of elevated tariff measures in 2025 has created material downstream effects across sourcing, manufacturing strategy, and procurement practices for wound biologics. Tariffs applied to imported raw materials, finished devices, and biologic components have increased landed costs and prompted manufacturers to reassess component sourcing, with a renewed emphasis on nearshoring and supply base diversification. In turn, contract manufacturers and suppliers have needed to revisit costing models and inventory strategies to preserve margins while ensuring uninterrupted supply to clinical customers.

These trade policy shifts have also influenced clinical adoption patterns indirectly. Procurement teams within hospitals and wound care centers are placing greater weight on total cost of ownership and supply certainty when evaluating supplier partnerships; products that offer simplified handling and reduced dependence on imported ancillary materials gain a comparative advantage. Further, some innovators are accelerating localized manufacturing investments and technology transfers to mitigate tariff exposure and shorten lead times. Overall, the 2025 tariff environment has elevated supply chain strategy to a core commercial imperative, making resilience, flexibility, and cost transparency critical for sustained market participation.

A granular segmentation analysis linking product modalities, clinical indications, care settings, and distribution channels to strategic commercialization opportunities

Detailed segmentation illuminates distinct value drivers, clinical use cases, and commercial pathways across product, application, end user, and distribution channel categories. Based on product type, the therapeutic set includes Collagen, Growth Factors, Platelet Derivatives, and Skin Substitutes; within Collagen formulations, bovine, equine, and porcine sources present differing immunogenic and handling profiles that affect clinician preference and regulatory strategy. The Growth Factors category encompasses epidermal growth factor, fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor, each with unique mechanisms that guide indication targeting and combination approaches. Platelet Derivatives are represented by platelet-rich fibrin and platelet-rich plasma, which are distinctive for being autologous, point-of-care interventions that shift procedural workflows. Skin Substitutes include biological dermal, composite dermal, and synthetic dermal constructs, with trade-offs between biological integration and manufacturing consistency.

Turning to application-based segmentation, acute wounds, burns, chronic wounds, and surgical wounds define different clinical endpoints and evidence expectations; burns subdivide into second-degree and third-degree presentations while chronic wounds include diabetic foot ulcers, pressure ulcers, and venous leg ulcers, each requiring tailored therapeutic strategies. End-user segmentation spans ambulatory surgical centers, home care, hospitals, and wound care centers, a mix that underscores varying procurement cycles, clinician competencies, and procedural settings. Finally, distribution channels are broadly offline and online, the former encompassing traditional clinical distributors and hospital supply chains and the latter growing through direct-to-provider and institutional e-commerce platforms. Integrating these segment dimensions reveals where clinical need, operational feasibility, and commercial scale align to favor specific technologies and go-to-market approaches.

Comparative regional intelligence revealing how regulatory regimes, payer priorities, and care infrastructure determine pathways to adoption across global markets

Regional dynamics shape technology adoption, reimbursement policy, and supply chain strategy in distinct ways across the Americas, Europe, Middle East & Africa, and Asia-Pacific markets. In the Americas, strong clinical infrastructure and established wound care specialty networks favor early adoption of novel biologics that demonstrate clinical differentiation and operational efficiency. These markets also prioritize evidence generation through real-world studies and integrated care pathways, creating demand for products that can show patient-centric outcomes.

In Europe, Middle East & Africa, heterogeneous regulatory regimes and payer systems require localized market access strategies, with some territories emphasizing cost-effectiveness and centralized procurement and others relying on specialist centers to champion innovations. The Asia-Pacific region exhibits rapid expansion in clinical capacity and manufacturing investment, fostering both demand and the potential for regional production scale. Across these geographies, differences in clinician training, reimbursement levers, and supply chain infrastructure mean that manufacturers must adopt region-specific evidence plans, distribution partnerships, and regulatory strategies to realize adoption at scale.

An assessment of competitive positioning and strategic moves that drive differentiation across innovation pipelines, manufacturing scale, and evidence-generation capabilities

Competitive dynamics within wound biologics are defined by differentiated science platforms, manufacturing capabilities, and evidence portfolios. Leading technology developers are investing in next-generation scaffold chemistries, multi-factor growth factor combinations, and standardized autologous processing systems, while contract manufacturers and component suppliers are scaling capabilities to meet stringent biologics quality and sterility demands. Strategic activity also includes partnerships between clinical leaders and product developers to co-design handling and application protocols that align with real-world workflows.

Moreover, go-to-market differentiation increasingly hinges on post-marketing data capture, real-world evidence generation, and health economic modeling that speak to payers and hospital purchasing. Some companies are prioritizing vertically integrated approaches to control supply chain risks, while others are forming alliances to expand distribution reach into ambulatory and home care channels. As market maturity advances, expect consolidation around integrated platforms that combine robust clinical outcomes with scalable manufacturing and reliable distribution footprints, thereby setting a higher bar for new entrants.

Concrete, prioritized actions for manufacturers and providers to align innovation priorities, fortify supply chains, and accelerate clinical and payer adoption in wound biologics

Industry leaders should adopt a coordinated set of actions to capitalize on scientific advances while managing commercial and operational risks. First, align R&D prioritization with care setting needs by developing products that meet the handling, storage, and application realities of hospitals, wound care centers, ambulatory surgical centers, and home care providers. Second, enhance supply chain resilience through diversified sourcing, nearshoring options, and strategic inventory policies that mitigate exposure to trade policy shifts and logistical disruptions.

Third, invest in rigorous clinical and health economic evidence that addresses payer concerns and facilitates pathway adoption; pragmatic trials and real-world registries can accelerate reimbursement conversations. Fourth, tailor regional market access plans that reflect local regulatory frameworks and procurement dynamics, ensuring that market entry sequences are optimized for reimbursement and clinician engagement. Finally, explore partnership models that bundle products with training, digital tracking, and outcome measurement to create differentiated value propositions that capture both clinical and economic stakeholders.

A transparent mixed-methods research framework combining clinician interviews, technical dossier review, and supply chain analysis to validate clinically and commercially relevant findings

This research synthesis draws on a mixed-methods approach that integrates primary qualitative interviews, secondary literature review, product technical dossiers, and supply chain mapping to construct a rigorous and actionable view of the wound biologics sector. Primary inputs include structured interviews with clinicians across hospital settings, wound care specialists, procurement leaders, regulatory experts, and manufacturing partners to capture real-world usage patterns, unmet clinical needs, and sourcing considerations. These perspectives were triangulated with regulatory guidance, peer-reviewed scientific literature, and product labeling information to validate mechanism-of-action claims and safety profiles.

In addition, supply chain analyses employed trade flow data, component sourcing reviews, and contract manufacturing assessments to illuminate tariff exposure and manufacturing risk. Segmentation frameworks were populated by mapping product characteristics to clinical indications and end-user workflows, and distribution channel analysis evaluated transactional friction points and digital adoption trends. Throughout, findings were cross-validated through iterative stakeholder feedback to ensure relevance and practical applicability for commercial and clinical decision-makers.

A forward-looking synthesis emphasizing the imperative for integrated strategies across R&D, supply chain, and market access to secure durable advantage in wound biologics

In conclusion, the wound biologics field stands at an inflection point where scientific progress, shifting care models, and commercial pressures converge to create both opportunity and complexity. Technologies that marry robust biological function with practical clinical handling and supply reliability will win early adoption. Concurrently, changes in trade policy and reimbursement expectations mean that manufacturers must be strategic about where and how they produce, price, and evidence their products.

Looking forward, organizations that integrate cross-functional planning-from R&D and regulatory to supply chain and market access-will be best positioned to capture durable value. Success will depend on demonstrating real-world outcomes, maintaining manufacturing and distribution resilience, and executing regionally nuanced commercialization strategies that reflect distinct payer and clinical landscapes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of point-of-care autologous platelet rich plasma systems in ambulatory wound care settings
  • 5.2. Expansion of allogeneic stem cell therapies for chronic diabetic foot ulcers and venous leg ulcers
  • 5.3. Integration of 3D bioprinting technology for customized extracellular matrix scaffolds in wound repair
  • 5.4. Increasing focus on cost effectiveness and reimbursement pathways for advanced biologic wound treatments
  • 5.5. Regulatory acceleration of human placental amnion membrane products under breakthrough device designations
  • 5.6. Growing interest in combination therapies pairing growth factors with bioactive nanofiber matrices for faster healing
  • 5.7. Emergence of telemedicine enabled wound monitoring platforms combined with biologic therapy management tools
  • 5.8. Development of pathogen reduced and decellularized xenograft membranes to minimize immunogenic response in chronic wounds

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Wound Biologics Market, by Product Type

  • 8.1. Collagen
    • 8.1.1. Bovine Collagen
    • 8.1.2. Equine Collagen
    • 8.1.3. Porcine Collagen
  • 8.2. Growth Factors
    • 8.2.1. Epidermal Growth Factor
    • 8.2.2. Fibroblast Growth Factor
    • 8.2.3. Platelet Derived Growth Factor
    • 8.2.4. Vascular Endothelial Growth Factor
  • 8.3. Platelet Derivatives
    • 8.3.1. Platelet Rich Fibrin
    • 8.3.2. Platelet Rich Plasma
  • 8.4. Skin Substitutes
    • 8.4.1. Biological Dermal
    • 8.4.2. Composite Dermal
    • 8.4.3. Synthetic Dermal

9. Wound Biologics Market, by Application

  • 9.1. Acute Wounds
  • 9.2. Burns
    • 9.2.1. Second Degree Burns
    • 9.2.2. Third Degree Burns
  • 9.3. Chronic Wounds
    • 9.3.1. Diabetic Foot Ulcer
    • 9.3.2. Pressure Ulcer
    • 9.3.3. Venous Leg Ulcer
  • 9.4. Surgical Wounds

10. Wound Biologics Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Home Care
  • 10.3. Hospitals
  • 10.4. Wound Care Centers

11. Wound Biologics Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Wound Biologics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Wound Biologics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Wound Biologics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. 3M Company
    • 15.3.2. Organogenesis Inc.
    • 15.3.3. Smith & Nephew plc
    • 15.3.4. Molnlycke Health Care AB
    • 15.3.5. Integra LifeSciences Holdings Corporation
    • 15.3.6. MiMedx Group, Inc.
    • 15.3.7. Celularity, Inc.
    • 15.3.8. Avita Medical Ltd.
    • 15.3.9. Alliqua BioMedical, Inc.
    • 15.3.10. CollPlant Biotechnologies Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL WOUND BIOLOGICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. WOUND BIOLOGICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. WOUND BIOLOGICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. WOUND BIOLOGICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL WOUND BIOLOGICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL WOUND BIOLOGICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BOVINE COLLAGEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BOVINE COLLAGEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BOVINE COLLAGEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BOVINE COLLAGEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BOVINE COLLAGEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BOVINE COLLAGEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY EQUINE COLLAGEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY EQUINE COLLAGEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY EQUINE COLLAGEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY EQUINE COLLAGEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY EQUINE COLLAGEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY EQUINE COLLAGEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PORCINE COLLAGEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PORCINE COLLAGEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PORCINE COLLAGEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PORCINE COLLAGEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PORCINE COLLAGEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PORCINE COLLAGEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY FIBROBLAST GROWTH FACTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY FIBROBLAST GROWTH FACTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY FIBROBLAST GROWTH FACTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY FIBROBLAST GROWTH FACTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY FIBROBLAST GROWTH FACTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY FIBROBLAST GROWTH FACTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVED GROWTH FACTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVED GROWTH FACTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVED GROWTH FACTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVED GROWTH FACTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVED GROWTH FACTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVED GROWTH FACTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY VASCULAR ENDOTHELIAL GROWTH FACTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET RICH FIBRIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET RICH FIBRIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET RICH FIBRIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET RICH FIBRIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET RICH FIBRIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET RICH FIBRIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET RICH PLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET RICH PLASMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET RICH PLASMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET RICH PLASMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET RICH PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PLATELET RICH PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BIOLOGICAL DERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BIOLOGICAL DERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BIOLOGICAL DERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BIOLOGICAL DERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BIOLOGICAL DERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BIOLOGICAL DERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COMPOSITE DERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COMPOSITE DERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COMPOSITE DERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COMPOSITE DERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COMPOSITE DERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY COMPOSITE DERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SYNTHETIC DERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SYNTHETIC DERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SYNTHETIC DERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SYNTHETIC DERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SYNTHETIC DERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SYNTHETIC DERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY ACUTE WOUNDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY ACUTE WOUNDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY ACUTE WOUNDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY ACUTE WOUNDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY ACUTE WOUNDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY ACUTE WOUNDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BURNS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BURNS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BURNS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BURNS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BURNS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY BURNS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SECOND DEGREE BURNS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SECOND DEGREE BURNS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SECOND DEGREE BURNS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SECOND DEGREE BURNS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SECOND DEGREE BURNS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SECOND DEGREE BURNS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY THIRD DEGREE BURNS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY THIRD DEGREE BURNS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY THIRD DEGREE BURNS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY THIRD DEGREE BURNS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY THIRD DEGREE BURNS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY THIRD DEGREE BURNS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY DIABETIC FOOT ULCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY DIABETIC FOOT ULCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY DIABETIC FOOT ULCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY DIABETIC FOOT ULCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY DIABETIC FOOT ULCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY DIABETIC FOOT ULCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PRESSURE ULCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PRESSURE ULCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PRESSURE ULCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PRESSURE ULCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PRESSURE ULCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY PRESSURE ULCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY VENOUS LEG ULCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY VENOUS LEG ULCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY VENOUS LEG ULCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY VENOUS LEG ULCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY VENOUS LEG ULCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY VENOUS LEG ULCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SURGICAL WOUNDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SURGICAL WOUNDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SURGICAL WOUNDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SURGICAL WOUNDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SURGICAL WOUNDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY SURGICAL WOUNDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY WOUND CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY WOUND CARE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY WOUND CARE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY WOUND CARE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY WOUND CARE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY WOUND CARE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY OFFLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY OFFLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL WOUND BIOLOGICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE WOUND BIOLOGICS MARKET SIZE, BY SKIN SUBSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPE WOUND BIOLOGICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPE WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPE WOUND BIOLOGICS MARKET SIZE, BY BURNS, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPE WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPE WOUND BIOLOGICS MARKET SIZE, BY CHRONIC WOUNDS, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPE WOUND BIOLOGICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPE WOUND BIOLOGICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPE WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 322. EUROPE WOUND BIOLOGICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 323. MIDDLE EAST WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 324. MIDDLE EAST WOUND BIOLOGICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 325. MIDDLE EAST WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 326. MIDDLE EAST WOUND BIOLOGICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 327. MIDDLE EAST WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2018-2024 (USD MILLION)
  • TABLE 328. MIDDLE EAST WOUND BIOLOGICS MARKET SIZE, BY COLLAGEN, 2025-2032 (USD MILLION)
  • TABLE 329. MIDDLE EAST WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2018-2024 (USD MILLION)
  • TABLE 330. MIDDLE EAST WOUND BIOLOGICS MARKET SIZE, BY GROWTH FACTORS, 2025-2032 (USD MILLION)
  • TABLE 331. MIDDLE EAST WOUND BIOLOGICS MARKET SIZE, BY PLATELET DERIVATIVES, 2018-2024 (USD MILLION)
  • TABLE 332. MIDDLE EAST WOUND BIOLOGIC